Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab
Identificadores
Identificadores
Data de publicación
2015Título da revista
ANNALS OF ONCOLOGY
Tipo de contido
Publicación de congreso